In December, the U.S. Food and Drug Administration (FDA) approved crinecerfont capsules and oral solution adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH). Crinecerfont is a selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that directly […]
